Is paraoxonase 1 a marker of cardiovascular risk in youth with type 1 diabetes? (Study about 109 cases)

La Presse médicale
O FekihMohamed Fadhel Najjar

Abstract

We purpose to verify if paraoxonase 1 (PON1) activity may be a marker of cardiovascular risk in a young Tunisian population with type 1 diabetes (T1D). PON1 activity was measured by a kinetic method using paraoxon as substrate. The other parameters were determined by automated methods. One hundred and nine children and adolescents with T1D and 97 healthy subjects were involved in this study. PON1 activity and PON1/HDL-cholesterol ratio were significantly decreased in diabetics (303 ± 174 vs. 372 ± 180 U/L and 221 ± 139 vs. 298 ± 20 1U/mmol, P=0.006, P=0.002, respectively) compared to controls. A significant increase in total cholesterol, LDL-c and microalbuminuria was observed in diabetics compared to controls. PON1 activity was decreased by 9.5% in patients with diabetes duration ≥ 6 years, by 28.4% for those with fasting glycemia ≥ 7 mmol/L (P<0.001), by 14% in those with HbA1c ≥ 8% and by 12.3% for diabetics with dyslipidemia. PON1 activity is reduced when the number of cardiovascular risk factors increases (P<0.001). PON1 seems to be associated to cardiovascular risk markers in T1D. This result remains to be seen. Nevertheless, improving PON1 activity could be a significant target for reducing cardiovascular risk.

References

Sep 1, 1994·Kidney International·W F Keane
Apr 16, 2002·European Journal of Clinical Investigation·B MacknessM I Mackness
Mar 20, 2008·JAMA : the Journal of the American Medical Association·Tamali BhattacharyyaStanley L Hazen
Nov 18, 2008·Metabolism: Clinical and Experimental·Yukio IkedaKozo Hashimoto
Apr 21, 2009·Ageing Research Reviews·Francesco LescaiClaudio Franceschi
Oct 6, 2009·Clinica Chimica Acta; International Journal of Clinical Chemistry·Binita GoswamiV Mallika
Jun 5, 2012·Clinical Biochemistry·Christine Bobin-DubigeonJean-Marie Bard
Nov 10, 2012·Diabetes Research and Clinical Practice·Hiroshi MurakamiToshihiro Suda
Jan 7, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Uzma Urooj MalikShamshad Zarina
May 13, 2014·Asian Journal of Psychiatry·Hajer MabroukMohamed Fadhel Najjar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Related Papers

JAMA : the Journal of the American Medical Association
Eddie Vos
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
Daniel E Weiner, Mark J Sarnak
© 2021 Meta ULC. All rights reserved